Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6175-6180

  Larché, Jérôme ^a   Pouillot, Flavie ^b   Essoh, Christiane ^c,d   Libisch, Balázs ^e   Straut, Monica ^f   Lee, Je Chul ^g   Soler, Charles ^h   Lamarca, Richard ⁱ   Gleize, Elodie ⁱ   Gabard, Jér̂ome ^b   Vergnaud, Gilles ^c,d,j   Pourcel, Christine ^c,d  

^a Centre Hospitalier de Narbonne   (France)

^b Pherecydes Pharma   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CNRS   (France)

^e NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^f National Institute for Research in Microbiology and Immunology   (Romania)

^g Kyungpook National University School of Medicine   (South Korea)

^h PERCY MILITARY HOSPITAL   (France)

ⁱ Centre hospitalier de Narbonne   (France)

^j DGA/MRIS Mission Pour la Recherche et L'Innovation Scientifique   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; MONOBACTAM; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; BACTERIAL VIRULENCE; BACTERIOPHAGE; DISEASE PREDISPOSITION; DNA PURIFICATION; FRANCE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TANDEM REPEAT;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CROSS INFECTION; DNA, BACTERIAL; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FRANCE; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINISATELLITE REPEATS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84869219864     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01233-12     Document Type: Article

References (35)

1. Agodi A, et al. 2007. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med. 33:1155-1161.
2. Bush K, et al. 2011. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9:894-896.
3. Cholley P, et al. 2011. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J. Clin. Microbiol. 49:2578-2583.
4. CLSI. 2007. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
5. CLSI. 2010. Performance standards for antimicrobial disk susceptibility tests; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Comeau AM, Tetart F, Trojet SN, Prere MF, Krisch HM. 2007. Phageantibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2:e799. doi:10.1371/journal.pone.0000799.
7. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42:5644-5649.
8. Denamur E, Picard B, Decoux G, Denis JB, Elion J. 1993. The absence of correlation between allozyme and rrn RFLP analysis indicates a high gene flow rate within human clinical Pseudomonas aeruginosa isolates. FEMS Microbiol. Lett. 110:275-280.
9. Empel J, et al. 2007. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J. Clin. Microbiol. 45:2829-2834.
10. Falagas ME, et al. 2005. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis. 5:24. doi:10.1186/1471-2334-5-24.
11. Giske CG, et al. 2006. Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J. Clin. Microbiol. 44:4309-4315.
12. Juan C, et al. 2010. Metallo-beta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J. Antimicrob. Chemother. 65:474-478.
13. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28:591-595.
14. Kutter E, et al. 2010. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11:69-86.
15. Lee YC, et al. 2007. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea. J. Microbiol. 45:358-363.
16. Libisch B, Balogh B, Fuzi M. 2009. Identification of two multidrugresistant Pseudomonas aeruginosa clonal lineages with a countrywide distribution in Hungary. Curr. Microbiol. 58:111-116.
17. Libisch B, et al. 2008. Molecular typing indicates an important role for two international clonal complexes in dissemination of VIM-producing Pseudomonas aeruginosa clinical isolates in Hungary. Res. Microbiol. 159:162-168.
18. Maatallah M, et al. 2011. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 6:e25617. doi:10.1371/journal.pone. 0025617.
19. Magiorakos AP, et al. 2011. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18:268-281.
20. Merabishvili M, et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944. doi:10.1371/journal.pone.0004944.
21. Nakasone I, Kinjo T, Yamane N, Kisanuki K, Shiohira CM. 2007. Laboratory-based evaluation of the colorimetric VITEK-2 compact system for species identification and of the Advanced Expert System for detection of antimicrobial resistances: VITEK-2 compact system identification and antimicrobial susceptibility testing. Diagn. Microbiol. Infect. Dis. 58:191-198.
22. Nho SO, et al. 2008. Dissemination of the blaIMP-1 and blaVIM-2 metallo-beta-lactamase genes among genetically unrelated Pseudomonas aeruginosa isolates in a South Korean hospital. Int. J. Antimicrob. Agents 31:586-588.
23. Pirnay JP, et al. 2011. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28:934-937.
24. Postic B, Finland M. 1961. Observations on bacteriophage typing of Pseudomonas aeruginosa. J. Clin. Invest. 40:2064-2075.
25. Rhoads DD, et al. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 8:237-243.
26. Roberts RR, et al. 2009. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 49:1175-1184.
27. Samuelsen O, et al. 2010. Molecular epidemiology of metallo-beta- lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob. Agents Chemother. 54:346-352.
28. Sobral D, et al. 2012. A new highly discriminatory multiplex capillary-based MLVA assay as a tool for the epidemiological survey of Pseudomonas aeruginosa in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 31:2247-2256.
29. Stenholm AR, Dalsgaard I, Middelboe M. 2008. Isolation and characterization of bacteriophages infecting the fish pathogen Flavobacterium psychrophilum. Appl. Environ. Microbiol. 74:4070-4078.
30. Szmolka A, et al. 2009. Virulence and antimicrobial resistance determinants of human pathogenic and commensal strains of Pseudomonas aeruginosa. Acta Microbiol. Immunol. Hung. 56:399-402.
31. Viedma E, et al. 2009. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extendedspectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53:4930-4933.
32. Vu-Thien H, et al. 2007. Multiple-locus variable-number tandem-repeat analysis for longitudinal survey of sources of Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Clin. Microbiol. 45:3175-3183.
33. Wright A, Hawkins CH, Anggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34:349-357.
34. Yang H, Liang L, Lin S, Jia S. 2010. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol. 10:131. doi:10.1186/1471-2180-10-131.
35. Zhang Q-G, Buckling A. 2012. Phages limit the evolution of bacterial antibiotics resistance in experimental microcosms. Evol. Appl. 5:575-582.